Fosamax & Jaw Death
The U.S. Food and Drug Administration has issued a warning about the potential risk of Osteonecrosis of the jaw, often called "jaw death" in patients using Fosamax (bisphosphonate), Actonel and Boniva, medications used for the treatment of osteoporosis. Caused by a restriction of blood flow to the jaw, jawbone tissue death results in serious and irreversible damage to the jaw.
According to published reports, Fosamax, a Merck product, has been linked to thousands of cases of jaw death, jawbone decay or osteonecrosis. Although most of the reported cases of Fosamax-related osteonecrosis have been in cancer patients treated intravenously, some have also occurred in patients experiencing postmenopausal osteoporosis.
At Pogust Braslow & Millrood, protecting our clients is our primary goal. We recognize that drug companies are under an obligation to warn about the known risks of their products. When they fail to do so, they may be held responsible for the injuries or deaths that are the consequence of their inaction.
If you or a loved one has experienced osteonecrosis or jaw death while taking Fosamax, you should immediately contact the attorneys at Pogust Braslow & Millrood, where Protecting Consumers Is Our Primary Goal. Just fill out this form, click here to send us an email or call us at (610) 941-4204.
|
